NIR-II Imaging-Guided Photothermal Activation of a TRPV4-Targeted Nanoplatform Delivering Cycloastragenol to Promote Microglia Reprogramming and α-Synuclein Clearance in Parkinson's Disease - PubMed
4 hours ago
- #NIR-II Imaging
- #Microglia Reprogramming
- #Parkinson's Disease
- Engineered a NIR-II phototheranostic nanoplatform (CAG/FD1080@MM-aTRPV4) for Parkinson's disease (PD) therapy.
- Targets both α-synuclein (α-syn) aggregation and microglia-mediated neuroinflammation.
- Uses cycloastragenol (CAG) from Astragalus to reprogram microglial metabolism.
- Enhances lysosomal function via photothermal activation of the TRPV4/CaMKKβ/AMPK/mTOR pathway.
- Enables dual-modality NIR-II photoacoustic-fluorescence imaging for real-time monitoring of microglial dynamics and α-syn clearance.
- Demonstrated efficacy in vitro (α-syn-treated microglia) and in vivo (α-syn-overexpressing mouse model).
- Presents a novel photothermal immunomodulation strategy using a Chinese herb-derived compound.